In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Endo International (ENDP), with a price target of $9. The company’s shares closed yesterday at $6.51, close to its 52-week low of $5.92.
Rivkind Koffler noted:
“We remain sidelined on ENDP primarily due to the opioid litigation overhang, and we reiterate our Neutral rating and $9 PT. On a positive note, we believe the CCH Cosmetic program in cellulite is evolving nicely and could still attract strategic interest. The picture may also brighten if Purdue declares bankruptcy.”
According to TipRanks.com, Koffler is a 2-star analyst with an average return of 0.2% and a 38.5% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Assertio Therapeutics Inc.
Currently, the analyst consensus on Endo International is a Moderate Buy with an average price target of $13.36, a 105.2% upside from current levels. In a report issued on April 29, Piper Jaffray also maintained a Hold rating on the stock with a $11 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.50 and a one-year low of $5.92. Currently, Endo International has an average volume of 3.47M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products.
